High Efficacy of Therapeutic Equine Hyperimmune Antibodies Against SARS-CoV-2 Variants of Concern
Loading...
Date
Authors
Moreira Soto, Andrés
Gutiérrez, José María
Alape Girón, Alberto
Drexler, Jan Felix
Arguedas Gómez, Mauricio
Brenes Porras, Hebleen
Buján Boza, Willem Aart
Corrales Aguilar, Eugenia
Díaz Oreiro, Cecilia
Echeverri McCandless, Ann
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
SARS-CoV-2 variants of concern show reduced neutralization by vaccine-induced and
therapeutic monoclonal antibodies; therefore, treatment alternatives are needed. We
tested therapeutic equine polyclonal antibodies (pAbs) that are being assessed in clinical
trials in Costa Rica against five globally circulating variants of concern: alpha, beta,
epsilon, gamma and delta, using plaque reduction neutralization assays. We show that
equine pAbs efficiently neutralize the variants of concern, with inhibitory concentrations
in the range of 0.146–1.078µg/mL, which correspond to extremely low concentrations
when compared to pAbs doses used in clinical trials. Equine pAbs are an effective, broad
coverage, low-cost and a scalable COVID-19 treatment.
Description
Keywords
Equine antibodies, SARS-CoV-2, Therapy, Variant of concern, PRNT titers 50, Neutralization test, COVID-19, VIROLOGÍA
Citation
https://www.frontiersin.org/articles/10.3389/fmed.2021.735853/full